
ET Intelligence Group says a semaglutide relaunch and an upcoming US biosimilar decision will be central to Dr Reddy’s recovery prospects.
Dr Reddy’s Laboratories may face another year of earnings decline in FY27 before a potential recovery in FY28, according to ET Intelligence Group. The outlook depends on a planned generic semaglutide relaunch, an abatacept biosimilar launch in the US and continued strength in its domestic business.
The semaglutide relaunch is scheduled for November 2026, after temporary supply disruptions linked to challenges scaling up active pharmaceutical ingredient production. The company has reiterated a target of selling six to seven million pens this year, with Canada and other international markets expected to lead initial volumes.
Dr Reddy’s sees a longer-term annual opportunity of 12 million to 15 million pens. Larger markets are expected to contribute meaningfully later, the article said.
A US regulatory decision on the company’s abatacept biosimilar is expected in December 2026. Commercial momentum may take a few quarters to build as the drug is added to formularies, while the company expects the product to have meaningful market-share potential.
The company’s domestic formulations business grew in the September quarter, supported by chronic therapies and a broader specialty portfolio. That strength was offset by lower Revlimid sales in North America and weakness in its active pharmaceutical ingredient business, according to ET Intelligence Group.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.